NDAORALTABLETPriority Review
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
Priority Review
NUPLAZID (pimavanserin tartrate) by Acadia Pharmaceuticals is unclear. First approved in 2016.
Drug data last refreshed 17h ago · AI intelligence enriched 22h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUPLAZID (pimavanserin tartrate) is an oral small-molecule antipsychotic approved in 2016 that works primarily through inverse agonist and antagonist activity at serotonin 5-HT2A receptors, with secondary activity at 5-HT2C receptors. The mechanism of action remains incompletely characterized but appears distinct from traditional dopamine-blocking antipsychotics. Indication details are not specified in available data.
$596MPart D
Peak11.0 years to LOEProduct is at peak commercial maturity with $596M in annual Part D spending, supporting stable commercial team operations and established field presence.
Mechanism of Action
unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT 2A receptors and to a lesser extent at serotonin 5-HT 2C receptors.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Acadia Pharmaceuticals is hiring 1 role related to this product
Worked on NUPLAZID at Acadia Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.